A Randomised, Double-blind (Sponsor Unblind), Placebo-controlled, Two Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of Single or Repeat Doses of GSK2793660 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 11 Aug 2017
At a glance
- Drugs GSK 2793660 (Primary)
- Indications Bronchiectasis
- Focus Adverse reactions; First in man
- Sponsors GlaxoSmithKline
- 11 Aug 2017 Results published in the British Journal of Clinical Pharmacology
- 19 Apr 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
- 14 Sep 2014 Planned End Date changed from 1 Jun 2014 to 1 Sep 2014 as reported by ClinicalTrials.gov.